Skip to main content
. 2021 Feb 4;106(5):1345–1351. doi: 10.1210/clinem/dgab065

Figure 1.

Figure 1.

Cumulative incidence of cardiovascular outcomes. DU, dulaglutide; HR, hazard ratio; MACE, composite end point of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular or unknown causes; PL, placebo.